Streetbeat News

DGNOF

Diagnos Inc.

Industry

Software Publishers

Open

0.22

Mkt cap

21M

Volume

24K

High

0.22

P/E Ratio

-7.00

52-wk high

0.31

Low

0.21

Div yield

N/A

52-wk low

0.17

Diagnos Inc. is filing for Saudi FDA authorization for its AI-assisted CARA SYSTEM, a medical device aimed at early detection of health issues. The company is collaborating with Kanhoor Medical for the Saudi market.

Portfolio Pulse from

March 12, 2025 | 1:30 pm

Diagnos Inc. plans to amend the terms of $590,000 in unsecured convertible debentures issued in a private placement from March 2022. This move could impact the company's financial strategy and investor sentiment.

Portfolio Pulse from

February 28, 2025 | 7:45 pm

Diagnos Inc. is filing for FDA pre-market authorization for its AI-powered CARA SYSTEM, engaging Ora as a regulatory specialist.

Portfolio Pulse from

February 25, 2025 | 2:30 pm

Diagnos Inc. will present at the Centurion One Capital 8th Annual Toronto Growth Conference, showcasing its AI-based FLAIRE platform for early detection of health issues.

Portfolio Pulse from

February 24, 2025 | 4:00 pm

Diagnos announced a correction to its previous press release regarding a private placement. The original figures for the number of units, gross proceeds, and cash remuneration to finders were incorrect.

Portfolio Pulse from

February 14, 2025 | 8:45 pm

Diagnos Inc. has received a CA$400,000 financial contribution from the Government of Canada to support its international marketing strategy for its CARA platform.

Portfolio Pulse from

January 30, 2025 | 7:00 pm

Diagnos Inc. will present at The Microcap Conference 2025, showcasing its AI-based FLAIRE platform for early detection of health issues. The event is a key opportunity for growth-focused companies and investors.

Portfolio Pulse from

January 28, 2025 | 8:00 pm

Diagnos Inc. has engaged Outside The Box Capital Inc. to provide marketing and promotional services for its AI-based FLAIRE platform.

Portfolio Pulse from

January 13, 2025 | 8:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.